Inosine

Phase 2Small molecule

MMichael Alan Schwarzschild

Inosine is one of 82 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Breast CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

Prolia

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Voltaren

Novartis

Preclinical

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Inosine

MMichael Alan Schwarzschild

Phase 2

1 9

Tricor

JJagotec

Preclinical

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Parkinson's Disease

NCT07170475

Clinical

Trials by Indication[1]

Parkinson's Disease3 trials

Study of Urate Elevation in Parkinson's Disease, Phase 3

Completed·MMichael Alan Schwarzschild·Phase 3·NCT02642393·298 enrolled

A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease

Recruiting·FFujita Health University·Phase 1·NCT07170475·24 enrolled

Safety of Urate Elevation in Parkinson's Disease

Completed·TThe Parkinson Study Group·Phase 2·NCT00833690·75 enrolled

Amyotrophic Lateral Sclerosis2 trials

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

Completed·MMassachusetts General Hospital·Phase 1·NCT02288091·32 enrolled

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

Completed·MMassachusetts General Hospital·Phase 2·NCT03168711·48 enrolled

Multiple Sclerosis1 trial

Treatment of Multiple Sclerosis Using Over the Counter Inosine

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00067327·30 enrolled

Breast Cancer1 trial

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Completed·FFudan University·Phase 2·NCT06355024·10 enrolled

Interaction1 trial

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Completed·MMichael Alan Schwarzschild·Phase 1·NCT02614469·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Inosine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inosine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inosine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Michael Alan Schwarzschild company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMichael Alan Schwarzschild

Inosine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Parkinson's Disease3 trials

Amyotrophic Lateral Sclerosis2 trials

Multiple Sclerosis1 trial

Breast Cancer1 trial

Interaction1 trial

References

Drug Info

Quick Facts

Related News